Why We’re Talking about CVMD

What is CVMD?

As science progresses, the understanding of the intersection between cardiovascular (CV), renal and metabolic diseases (MD) has expanded. Clinical overlap exists between these diseases and their associated complications, which explains why it is so complex to reduce CV risk. Currently, CV disease (CVD) is the number one cause of death across the globe1, and constitutes an enormous burden not only on patients’ overall health and well-being, but on society and healthcare systems. CVD is the leading cause of death in people with chronic kidney disease (CKD) and diabetes.2,3 Adults with diabetes are two to four times more likely to die from CVD than adults without diabetes.4 Because of the impact of CVD on the health of so many people, it is important to continue exploring the interconnectedness of CV, renal and metabolic diseases, instead of managing each condition in isolation.

Cardiovascular, renal and metabolic diseases (CVMD) together form one of AstraZeneca’s main therapeutic areas of focus. By following the science to understand more clearly the underlying links between the heart, kidney and pancreas, we are investing in a portfolio of medicines aiming to protect organs and improve outcomes by slowing disease progression, reducing risks, and tackling co-morbidities to improve treatment practices and CVMD health for millions of patients worldwide.

 


What is #CVMD?

As a company that is committed to researching and development treatments for the several diseases that fall within CVMD, we’re focused on taking an integrated approach to unifying our messages on social media and helping to bring people together to learn more about the interconnectedness of CVMD. Our goal is to see CVMD discussed holistically online, easily connecting these closely related topics.  

Using #CVMD on social media helps us achieve this unity, and is our way of bringing news and information to all those affected by these diseases. Whether someone is living with CVD, diabetes, chronic kidney disease, or hyperkalemia, CVMD news is relevant to all these patients.

Follow @AstraZeneca on Twitter and see what’s new with #CVMD. Join the conversation with your perspectives on CVMD and help break down the walls within this therapeutic area.  

References

  1. World Health Organization. Cardiovascular disease. World Heart Day 2017. http://www.who.int/cardiovascular_diseases/world-heart-day-2017/en/. Accessed 9 November 2017.
  2. International Diabetes Federation. IDF Diabetes Atlas, 7th ed. Brussels, Belgium: International Diabetes Federation, 2015.
  3. National Institutes of Health. Chronic Kidney Disease and Kidney Failure. 19 March 2013 Available at: https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=34. Accessed 7 November 2017.
  4. American Heart Association. Cardiovascular Disease & Diabetes. 14 April 2017. Available: http://www.heart.org/HEARTORG/Conditions/More/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.WgLM8mi0P4Y. Accessed 7 November 2017

Veeva ID: Z4-7956
Date of next review: November 2018